Get started
Author

Драй Роман Васильевич

Observed names: R. V. Drai, R. V. Dray, R.V. Drai, ROMAN V. DRAI, Roman Drai, Roman Dray, Roman V Drai, Roman V. Drai, Драй Р. В., Р.В. Драй
Institution: GEROPHARM (Russia)
ORCID: 0000-0003-4594-6097
Observed ORCID: 0000-0003-4594-6097
OpenAlex ID: A5022584888
The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug
2025 · I. A. Lugovik, A. V. Babina, et al. · Drug development & registration · 13
PDF
Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus ® ): a randomized open-label clinical trial
2020 · Tatiana L Karonova, Anna A Mosikian, et al. · Journal of Comparative Effectiveness Research · 12
Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid ® Penfill ® ) in Type 1 diabetes mellitus
2021 · Tatiana L Karonova, Alexander Y Mayorov, et al. · Journal of Comparative Effectiveness Research · 10
Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure
2022 · Roman V. Drai, Tatiana L. Karonova, et al. · Clinical Pharmacology in Drug Development · 9
PDF
Comparability of biosimilar romiplostim with originator: Protein characterization, animal pharmacodynamics and pharmacokinetics
2023 · Anna N. Arefeva, Igor E. Makarenko, et al. · Biologicals · 7
Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial
2020 · Alexander Y. Mayorov, Roman V. Drai, et al. · Diabetes Mellitus · 7
PDF
Dynamics of turnover of sugar-lowering drugs in the retail segment of the pharmaceutical market from 2020 to 2024
2025 · D. V. Kurkin, E. V. Makarova, et al. · Pharmacy & Pharmacology · 6
PDF
Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure
2024 · Ekaterina Koksharova, Roman Drai, et al. · Clinical Pharmacology in Drug Development · 6
Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in Type 2 diabetes mellitus patients
2020 · Alexandr Y Mayorov, Anna A Mosikian, et al. · Journal of Comparative Effectiveness Research · 6
Evolution of insulin therapy: past, present, future
2024 · D. V. Kurkin, D. A. Bakulin, et al. · Problems of Endocrinology · 5
PDF
Methodological and regulatory aspects of pharmaceutical development of biological products
2024 · D. V. Kurkin, E. I. Morkovin, et al. · Pharmacy & Pharmacology · 4
Overview of drugs approved by the FDA in 2022
2023 · D. V. Kurkin, E. I. Morkovin, et al. · Pharmacy & Pharmacology · 4
A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
2023 · Igor Makarenko, Artem Dorotenko, et al. · Pharmacology Research & Perspectives · 4
PDF
Quality Management in Pharmaceutical Development of Biotechnology-Derived Medicinal Products: Implementation and Evaluation
2023 · I. S. Giba, K. R. Salieva, et al. · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · 4
PDF
Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
2023 · D. V. Kurkin, D. A. Bakulin, et al. · Pharmacy & Pharmacology · 4
Modern Concepts of the Pathogenesis of Type 2 Diabetes Mellitus
2022 · D.V. Kurkin, E.I. Morkovin, et al. · Journal of Volgograd State Medical University · 4
PDF
Results of the Estimation of Biosimilarity of RinLiz® (LLC «GEROPHARM», Russia) and Humalog® (Lilly France, France) Using the Method of the Hyperinsulinemic Eulygemic Clamp on Healthy Voluntary
2020 · A. Yu. Mayorov, I. A. Fedotov, et al. · Drug development & registration · 4
PDF
Fixed ratio combinations GLP-1RA and basal insulin: literature review
2024 · D. V. Kurkin, D. A. Bakulin, et al. · Problems of Endocrinology · 3
PDF
Optimisation of induction conditions for a bacterial strain producing proinsulin aspart
2023 · I. A. Kornakov, Z. R. Khasanshina, et al. · Biological Products Prevention Diagnosis Treatment · 3
PDF
The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix ® 30 in Type 2 diabetes patients
2022 · Roman V Drai, Alexander Y Mayorov, et al. · Journal of Comparative Effectiveness Research · 3
Population Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim Biosimilar GP40141 and Reference Product in Healthy Volunteers to Evaluate Biosimilarity
2024 · Igor Makarenko, Aleksandr Petrov, et al. · Clinical Pharmacology in Drug Development · 2
Bioequivalence of Reference and Biosimilar Preparations of Premixed Biphasic Insulin Aspart: A Comparative Clamp Study
2023 · Artem Dorotenko, Igor Makarenko, et al. · Clinical Pharmacology in Drug Development · 2
Physicochemical and Functional Characterization of Medicinal Product Rinsulin® R
2023 · A. V. Babina, R. V. Drai, et al. · Drug development & registration · 2
PDF
PKPD Modeling and Simulations to Support Biosimilar Development of Biphasic Insulin Aspart 30
2022 · Aleksandr V. Petrov, Bella R. Zinnatulina, et al. · Clinical Pharmacology in Drug Development · 2
Experimental Validation of an In Vitro Method for Assessing Insulin-Dependent Glucose Uptake
2022 · A. N. Afanasyeva, V. B. Saparova, et al. · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · 2
PDF
Works count: 70
Citation count: 148
H-index: 6
I10-index: 3
Year
Topic
Type